Portola jumps on Priority Review for betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $6.33 (34%) to $25.06 after it said FDA accepted and granted Priority Review to the biotech’s NDA for betrixaban (PRT054021) for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. The PDUFA date is June 24, 2017.

The company also said EMA validated its MAA for the Factor Xa inhibitor in the same indication...